Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Plasmablastic Lymphoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Glioblastoma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 16Vincristine 12Prednisone 11Methotrexate 11Etoposide 9Cytarabine 9merphos 8blinatumomab 8venetoclax 7prednylidene 7pegaspargase 7deltacortene 7Specimen Handling 7Mercaptopurine 7Dexamethasone 7azathiopurine 6N,N-dicyclohexyl-isoborneol-10-sulfonamide 6Doxorubicin 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5Spinal Puncture 5Rituximab 5Leucovorin 5Biopsy 5fludarabine phosphate 4Stem Cell Transplantation 4Methylprednisolone 4Inotuzumab Ozogamicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Burkitt Lymphoma × varlilumab × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡